Research programme: tuberculosis therapeutics - Ginkgo Bioworks
Latest Information Update: 06 Dec 2022
At a glance
- Originator Zymergen
- Developer Ginkgo Bioworks
- Class Antituberculars; Small molecules
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Research Tuberculosis
Most Recent Events
- 17 Mar 2022 Tuberculosis therapeutics are available for licensing as of 17 Mar 2022. (https://www.zymergen.com/solutions/partners/)
- 06 Mar 2022 Zymergen receives grant from the Bill & Melinda Gates Foundation for tuberculosis and other therapeutics development
- 06 Mar 2022 Early research in Tuberculosis in USA (unspecified route)